cu-64 rituximab
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01598558)
Timeline
No events for the selected filters.
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 64-Copper
Oral
No
Parenteral
No
Topical
No
Also known as
- cu-64 rituximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01598558 | N/A | Jan 1, 2012 | Stanford University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1